Abbott Laboratories $ABT Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC reduced its position in Abbott Laboratories (NYSE:ABT) by 0.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,407,499 shares of the healthcare product maker’s stock after selling 134,395 shares during the quarter. Geode Capital Management LLC’s holdings in Abbott Laboratories were worth $4,790,674,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ABT. Invesco Ltd. boosted its holdings in shares of Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after acquiring an additional 4,713,135 shares during the period. Ninety One UK Ltd acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $336,815,000. Vanguard Group Inc. boosted its holdings in shares of Abbott Laboratories by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after acquiring an additional 2,402,408 shares during the period. Alliancebernstein L.P. boosted its holdings in shares of Abbott Laboratories by 51.0% in the third quarter. Alliancebernstein L.P. now owns 5,525,906 shares of the healthcare product maker’s stock valued at $740,140,000 after acquiring an additional 1,865,250 shares during the period. Finally, Capital International Investors boosted its holdings in shares of Abbott Laboratories by 2.5% in the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after acquiring an additional 1,478,076 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. The trade was a 1.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last three months. Insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Barclays decreased their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a report on Monday, April 20th. BTIG Research reaffirmed a “buy” rating and set a $131.00 price target on shares of Abbott Laboratories in a report on Monday, April 27th. Jefferies Financial Group decreased their price target on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a report on Friday, April 17th. UBS Group decreased their price target on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a report on Monday, April 20th. Finally, Wells Fargo & Company decreased their price target on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $119.09.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott won FDA clearance and EU CE Mark approval for Ultreon 3.0, an AI-powered coronary imaging tool that helps guide artery stent placement, which could support future med-tech growth. Abbott (ABT) Wins FDA and EU Approval for an AI-Powered Tool That Guides Artery Stent Placement
• Positive Sentiment: The company secured CE Mark for Libre Duo, the world’s first dual glucose-ketone sensing technology, expanding its diabetes care lineup and potentially strengthening its CGM franchise. Abbott secures CE Mark for world’s first dual glucose-ketone sensing technology for people with diabetes
• Positive Sentiment: Updated American Cancer Society guidelines reaffirmed Cologuard and Cologuard Plus as preferred noninvasive colorectal cancer screening options, reinforcing Abbott’s position in cancer diagnostics. ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
• Neutral Sentiment: Abbott’s diagnostics unit showed mixed first-quarter trends, with core lab growth offset by weakness in China and softer respiratory testing demand, suggesting an uneven outlook in that segment. How Abbott’s Diagnostics Unit Is Shaping Up Through the Rest of 2026
• Negative Sentiment: Goldman Sachs lowered its price target on Abbott to $113 from $121, even while maintaining a buy rating, adding some caution around near-term upside. Goldman Sachs adjusts price target on Abbott Laboratories to 113 from 121, maintains buy rating
• Negative Sentiment: Separately, commentary highlighted headwinds in Abbott’s nutrition business, which may be weighing on investor sentiment. Abbott Laboratories (ABT) Slid on Headwinds in Nutrition Business

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $85.70 on Thursday. The stock has a fifty day moving average price of $95.41 and a 200 day moving average price of $111.15. The company has a market cap of $149.27 billion, a PE ratio of 24.00, a P/E/G ratio of 1.45 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.